Ligand Pharmaceuticals Incorporated

NasdaqGM:LGND Stock Report

Market Cap: US$1.3b

Ligand Pharmaceuticals Management

Management criteria checks 3/4

Ligand Pharmaceuticals' CEO is Todd Davis, appointed in Dec 2022, has a tenure of 1.25 years. total yearly compensation is $5.82M, comprised of 0.8% salary and 99.2% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $4.30M. The average tenure of the management team and the board of directors is 1.3 years and 14.3 years respectively.

Key information

Todd Davis

Chief executive officer

US$5.8m

Total compensation

CEO salary percentage0.8%
CEO tenure1.3yrs
CEO ownership0.3%
Management average tenure1.3yrs
Board average tenure14.3yrs

Recent management updates

Recent updates

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Dec 19
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

Jun 14
Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

May 29
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07
Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27
Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year

Dec 31

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Dec 03
Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?

Oct 11
Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?

Ligand's Ailing Remdesivir Cash Cow

Oct 11

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Aug 19
Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Ligand: 2021 Is Pivotal

Jul 16

CEO Compensation Analysis

How has Todd Davis's remuneration changed compared to Ligand Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

US$54m

Sep 30 2023n/an/a

US$21m

Jun 30 2023n/an/a

US$41m

Mar 31 2023n/an/a

US$51m

Dec 31 2022US$6mUS$49k

-US$5m

Sep 30 2022n/an/a

US$23m

Jun 30 2022n/an/a

US$27m

Mar 31 2022n/an/a

US$45m

Dec 31 2021US$328kn/a

US$76m

Sep 30 2021n/an/a

US$68m

Jun 30 2021n/an/a

US$48m

Mar 31 2021n/an/a

US$39m

Dec 31 2020US$329kn/a

US$7m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$350kn/a

US$629m

Sep 30 2019n/an/a

US$594m

Jun 30 2019n/an/a

US$677m

Mar 31 2019n/an/a

US$764m

Dec 31 2018US$343kn/a

US$143m

Sep 30 2018n/an/a

US$179m

Jun 30 2018n/an/a

US$120m

Mar 31 2018n/an/a

US$53m

Dec 31 2017US$283kn/a

US$13m

Compensation vs Market: Todd's total compensation ($USD5.82M) is about average for companies of similar size in the US market ($USD5.10M).

Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.


CEO

Todd Davis (62 yo)

1.3yrs

Tenure

US$5,824,396

Compensation

Mr. Todd C. Davis, Ph D., serves as an Independent Director of Chromocell Therapeutics Corporation since January 2023 and its Chairman of the Board. He is Chief Executive Officer at Ligand Pharmaceuticals...


Leadership Team

NamePositionTenureCompensationOwnership
Todd Davis
CEO & Director1.3yrsUS$5.82m0.34%
$ 4.3m
Matthew Korenberg
President & COO1.3yrsUS$6.54m0.59%
$ 7.4m
Octavio Espinoza
Chief Financial Officer1.3yrsUS$3.27m0.17%
$ 2.1m
Andrew Reardon
Chief Legal Officer & Secretary1.3yrsUS$3.25m0.13%
$ 1.6m
Paul Hadden
Senior Vice President of Investments & Business Developmentno datano datano data
Simon Latimer
Head of Investor Relationsno datano datano data
Todd Pettingill
Director of Corporate Developmentno datano datano data
Audrey Warfield-Graham
Chief People Officer17.2yrsno datano data
Keith Marschke
Senior Vice President of Biology & Scientific Affairs6.2yrsno datano data
Vincent Antle
Senior Vice President of Technical Operations & QA - Capitsol6.2yrsno datano data
Patrick Lucy
Senior VP & CBO Protein Expression Businessno datano datano data
Karen Reeves
Senior VP of Clinical Strategy & Investmentsless than a yearno datano data

1.3yrs

Average Tenure

53yo

Average Age

Experienced Management: LGND's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Todd Davis
CEO & Director17yrsUS$5.82m0.34%
$ 4.3m
John Kozarich
Independent Chairman21yrsUS$586.60k0.22%
$ 2.7m
John LaMattina
Independent Director13.1yrsUS$481.16k0.15%
$ 1.9m
Stephen Sabba
Independent Director15.6yrsUS$571.60k0.16%
$ 2.0m
Jason Aryeh
Independent Director17.5yrsUS$483.66k0.44%
$ 5.6m
Shalendar Bhasin
Scientific Advisorno datano datano data
Jason Haas
Independent Director1.8yrsUS$490.57k0.017%
$ 214.0k
Nancy Gray
Independent Director6.6yrsUS$436.41k0.031%
$ 386.6k
Martine Zimmermann
Directorless than a yearno datano data

14.3yrs

Average Tenure

63yo

Average Age

Experienced Board: LGND's board of directors are seasoned and experienced ( 14.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.